Amayeza Abuntu (SA 2011) Mr. Godard, you previously worked in Europe for Baxter Edwards Life Sciences, what made you decide to move to South Africa in a smaller company? It is a purely romantic French story. I met my wife in France 10 years ago during a medical product training session that we had…
Eli Lilly (SA 2011) You were recently appointed at the head of Eli Lilly South African operations. What is the specific mission you have been given? Eli Lilly South Africa is in an interesting situation where we want to engage our personnel, recognize the importance of diversity and people development, and make sure that…
Dream CIS South Korea has a much shorter history of clinical trials than many other advanced economies. In your view, what is the potential for South Korea’s clinical trial industry today? The quality of Korean medical service is already top notch; it is truly world class. However, the environment here has been…
Bayer Healthcare South Africa Since we interviewed you in 2005, there have been many changes in the market, from consolidation, an increasing generic penetration, to new healthcare reforms… How have you integrated these changes in the company’s development, and to what extent does Bayer’s recent development reflect the market changes? The first change has…
Histostem After spending a large part of your career as a university professor, what drove you to create your own company, Histostem, in 2000? In 1993, I actually established a bone marrow bank for the first time in Korea when I was a professor of the Catholic University in Seoul, Korea.…
Aspen The Aspen Group identified Latin America as a “large developing market where it can leverage its substantial intellectual property portfolio and manufacturing infrastructure”. What was the original strategy behind getting the best from the Mexican market – specifically with the acquisition of the Latin America business from India-based Strides Arcolab…
Infinite Clinical Research We understand that Mexico has a lot of advantages for holding clinical trials, including the large population, access to specialized patient populations, higher patient retention rates and cheaper costs by up to 30% when compared to the United States and Europe. In your opinion, what is the most common reason…
Astellas Czech Republic Mr. Chadim, after Astellas was formed from the merger between Yamanouchi and Fujisawa, it became your job to lead its Czech subsidiary. Tapani Sura, your colleague at Astellas Poland, has told Focus Reports that in Poland, Astellas’ first year was a nightmare. “It is safe to say,” he remarked, that…
Stallergenes Czech Republic Mr. Tor, prior to joining Stallergenes in 2010, you had been with MSD for nearly two decades. After such a prolonged experience at a major global pharma player, why did you decide to move down the value chain to a smaller, considerably more specialized biopharmaceutical company like Stallergenes, and what…
Array As a Taiwanese national and Country Head of Novartis Taiwan, what is your opinion on the current state of the pharmaceutical industry in Taiwan, and what are your hopes for the future? I am of the opinion that it is going to get worse before it gets better. The National…
Ministry of Health (Republic of Serbia) Priorities and plans of the Ministry of Health If we entered an election year with a major reform plan, we would not succeed in putting such proposals into parliamentary procedure. Therefore, our aim is to adhere to the Action Plan of the Ministry of Health for 2011 which has been…
Commerce and Business Environment of Romania Within a broad assessment of Romania’s investment climate, there is no doubt that every country has some key factors upon which can be capitalized to attract foreign investors. In sum, how would you describe the current investment climate in Romania, and what are these factors that the country can leverage…
See our Cookie Privacy Policy Here